소세포폐암 환자의 항암제와 방사선 치료의 병합요법

Background: Small cell lung cancer is sensitive to chemotherapy and radiotherapy. Nevertheless, responders are still short-lived and succumb as a result of central nervous system metastases. Method: To improve the incidence of complete remission and the length of survival time we treated 17 patients with cyclophosphamide, vincristine, cisplatin and etoposide (COPE), combined with radiotherapy. Results: The four patients with limited disease had an 100% response rate (50% CR) and duration of response for 2 patient with CR were 64+weeks and 101+weeks. And duration of response for one evaluable patients with PR was 24 weeks. The 13 patients with extensive disease had an 92% response rate (38% CR) and duration of response of patients with CR was 17-130 weeks (median 58 week) and that of patients with PR was 17-48 weeks (median 18 week). The median duration of survival for all patients was 63 weeks. The durations of survival for 3 patients with LD were 64+ weeks, 101+ weeks and 104+ weeks, and median duration of survival for patients with ED was 60 weeks. Most of patients suffered from nausea, vomiting and alopecia but they were tolerable. Conclusion: We concluded that the COPE chemotherapy combined with radiotherapy has improved the incidence of complete remission and the length of survival time.